CRBU250117P5000
- 3.10
- 0.000.00%
Caribou Biosciences Newsroom
Caribou Biosciences to Present at 43rd Annual J.P. Morgan Healthcare Conference
BofA Securities Cuts Price Target on Caribou Biosciences to $11 From $13, Maintains Buy Rating
Caribou Biosciences Price Target Raised to $34 From $26 at Brookline
Caribou Biosciences Hires CFO From Codexis
Press Release: Caribou Biosciences Appoints Sri Ryali as Chief Financial Officer
Why Is Caribou Biosciences Inc. (CRBU) Among the Top CRISPR Stocks to Invest In?
Here's Why Caribou Biosciences (NASDAQ:CRBU) Must Use Its Cash Wisely
Caribou Biosciences (CRBU) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Caribou Biosciences Analyst Ratings
Citi Maintains Caribou Biosciences(CRBU.US) With Buy Rating, Cuts Target Price to $6
Express News | Caribou Biosciences Inc : Citigroup Cuts Target Price to $6 From $30
Caribou Biosciences Reports Q3 2024 Financial Results
Caribou Biosciences to Participate in Upcoming Investor Conferences
H.C. Wainwright Maintains Caribou Biosciences(CRBU.US) With Buy Rating, Maintains Target Price $9
Express News | HC Wainwright & Co. Reiterates Buy on Caribou Biosciences, Maintains $9 Price Target
Analysts Are Updating Their Caribou Biosciences, Inc. (NASDAQ:CRBU) Estimates After Its Third-Quarter Results
Caribou Biosciences' Strategic Advancements and Financial Efficiency Bolster Buy Rating
Evercore Maintains Caribou Biosciences(CRBU.US) With Hold Rating, Maintains Target Price $3
Caribou Bioscience GAAP EPS of -$0.38 Beats by $0.06, Revenue of $2.02M Misses by $1.07M